Elis: Disclosure of trading in own shares occured from April 7 to April 9, 2025
Disclosure of trading in own shares occurred from April 7 to April 9, 2025
Saint-Cloud, April 14, 2025
In accordance with the regulations on share buybacks, in particular Regulation (EU) 2016/1052, Elis hereby declares the purchases of its own shares made from April 7, 2025 to April 9, 2025 under the buyback program authorized by the 19th resolution of the General Shareholders' Meeting of May 23, 2024 and announced on March 6, 2025:
Aggregated presentation:
Issuer name
Issuer code(LEI)
Transaction date
ISIN Code
Daily total Volume (in number of shares)
Daily weighted average price of shares acquired (in euros)
Platform (MIC Code)
ELIS SA
969500UX71LCE8MAY492
04/07/2025
FR0012435121
89,197
19.2463
XPAR
ELIS SA
969500UX71LCE8MAY492
04/07/2025
FR0012435121
59,749
19.1855
DXE
ELIS SA
969500UX71LCE8MAY492
04/07/2025
FR0012435121
14,626
19.1860
TQE
ELIS SA
969500UX71LCE8MAY492
04/07/2025
FR0012435121
12,595
19.1877
AQE
ELIS SA
969500UX71LCE8MAY492
04/08/2025
FR0012435121
48,084
19.7506
XPAR
ELIS SA
969500UX71LCE8MAY492
04/08/2025
FR0012435121
26,494
19.7132
DXE
ELIS SA
969500UX71LCE8MAY492
04/08/2025
FR0012435121
6,940
19.6865
TQE
ELIS SA
969500UX71LCE8MAY492
04/08/2025
FR0012435121
5,897
19.7032
AQE
ELIS SA
969500UX71LCE8MAY492
04/09/2025
FR0012435121
97,673
19.8585
XPAR
ELIS SA
969500UX71LCE8MAY492
04/09/2025
FR0012435121
60,445
19.8443
DXE
ELIS SA
969500UX71LCE8MAY492
04/09/2025
FR0012435121
18,597
19.8507
TQE
ELIS SA
969500UX71LCE8MAY492
04/09/2025
FR0012435121
13,305
19.8306
AQE
Total
453,602
19.5816
The purpose of the own shares purchase operations is (i) to cover maturing performance share plans and to allocate free shares to employees as part of the contribution to the Elis for All 2025 international employee shareholding plan, and (ii) to be cancelled in accordance with the 30th resolution of the Combined General Meeting of May 23, 2024.
Contacts
Nicolas BuronDirector of Investor Relations, Financing & TreasuryPhone: + 33 (0)1 75 49 98 30 - nicolas.buron@elis.com
Charline LefaucheuxInvestor Relations Phone: + 33 (0)1 75 49 98 15 - charline.lefaucheux@elis.com
Attachment
Elis - Disclosure of trading in own shares occured from April 7 to April 9, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Times
44 minutes ago
- New York Times
Big Tech Is Finally Losing
It's easy to miss it amid the nonstop avalanche of news, but we are on the cusp of a technology revolution — one that could usher in an entirely new information landscape. After 30 years of shockingly few regulatory restraints, America's tech giants were beginning to operate almost like wrecking balls, slamming their weight into industry after industry and taking them out one after another. Boom. Uber crushed the taxi limousine business. Boom. Facebook toppled the news business. Boom. Amazon wiped out numerous small retailers. Finally, our courts are beginning to push back. In the past two months, courts have forced Apple to end its usurious tax on purchases made through apps on its phones, ruled that Google had abused its online ad monopoly and considered what consequences to impose on Google for what they concluded was an illegal dominance of the search market. A court has heard arguments about why Meta, which runs Facebook, should be forced to spin off popular rivals Instagram and WhatsApp, and allowed a case to proceed that alleges Amazon has abused its monopoly. Reining in Big Tech appears to be one of the few bipartisan policies that has spanned the Biden and Trump administrations, despite the tech titans' attempts to curry favor with the new president. Taken together, these developments could end years of stagnation and usher in more competition, smaller companies and better services. I personally can't wait for competition in the search market — as Google results have been getting worse, by many estimates, including my own. I'm tired of sifting through Google's increasingly cluttered and irrelevant search results, searching in vain for the latest news and instead finding only Reddit posts. I want a search engine for shopping that trawls the web for the best merchandise rather than just pulling from the sites that list items with Google. I want a search engine that doesn't allow ads to masquerade as reviews. I want a search engine that lets me control the amount of artificial intelligence summaries in my results. And there are probably even cooler search products that a new generation of search entrepreneurs will dream up. Google argues that A.I. search engines like Perplexity are already providing competition in the market. That is a mirage. As the judge in the Google antitrust case has described, none of Google's rivals can compete with it, given how much Google knows about what websites users click and stay on versus those they click and bounce from. Want all of The Times? Subscribe.
Yahoo
an hour ago
- Yahoo
Inter Scientific Supports Jupiter Research in Achieving EU Certification for First Handheld Liquid Inhalation Device
LIVERPOOL, United Kingdom, June 12, 2025 (GLOBE NEWSWIRE) -- Inter Scientific is pleased to announce its role, in collaboration with Jupiter Research LLC, as the regulatory partner for the first handheld Liquid Inhalation Device to receive regulatory approval under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone marks a significant step forward in the medical device landscape and opens the door for wider global access to innovative inhalation technologies. Jupiter Research, a pioneering company in the liquid vaporizer space, identified early in its development journey the importance of an expert regulatory partner. After an initial review process, Jupiter selected Inter Scientific based on its ability to meet the demands and complexity of the EU MDR. This decision proved instrumental in Jupiter's successful regulatory approval. 'Jupiter recognised very early in the process that external support would be beneficial,' stated Jupiter's Senior Director of Engineering, Jordan Walker. 'We chose Inter Scientific based on their expertise and felt they were efficient and professional throughout the contract, helping us achieve our goals and gain regulatory approval.' Walker continued, 'Inter Scientific provided expertise in the creation of the device's comprehensive Technical File, development of the required Quality Management System documentation, and delivery of tailored educational services to Jupiter's internal teams. This approach enabled a streamlined path to regulatory compliance.' David Lawson, Executive Director at Inter Scientific, commented:'At every stage of this rigorous certification process, Inter Scientific maintained a customer-focused approach, working closely with the Jupiter team and delivering timely, professional, and accurate support. We're proud to be recognised as a key contributor to this success and look forward to building on this achievement through continued collaboration on future regulatory initiatives.' Inter Scientific's in-depth understanding of the regulatory framework helped Jupiter design the device in line with medical classification requirements, prepare the necessary documentation, and respond effectively to regulatory feedback, which resulted in the successful approval of a first of its kind device now poised to make its mark in global healthcare. About Inter ScientificInter Scientific is an independent, accredited contract research organisation (CRO) providing regulatory science, product testing, and compliance services across highly regulated industries. With over a decade of experience, we support clients in the medical device, pharmaceutical, nicotine product, cosmetic, and novel food sectors. Inter Scientific operates to the highest quality standards, holding ISO/IEC 17025 accreditation and operating in accordance with Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP). Our expert team delivers scientifically robust, regulatory-ready data and strategic guidance to help clients navigate complex global regulations and bring compliant products to market with confidence. Inter Scientific Media Contact Razieh Alipour Digital Marketing Content in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
12 hours ago
- Bloomberg
Singapore Order Leads Unlicensed Crypto Exchanges to Weigh Exit
A final warning from Singapore's regulator has prompted major crypto exchanges operating in the country without a permit to plan for a hasty exit. Bitget and Bybit — top-10 exchange operators by volume with a presence in Singapore but no local license — plan to reorganize their teams, according to people familiar with the matter. Bitget will shift staff to jurisdictions including Dubai and Hong Kong, while Bybit is weighing similar moves, said the people, who refused to be identified as the plans are confidential.
